A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
NCT06693895
This study is recruiting at 16 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted varicella nor received a varicella vaccination.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chickenpox
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 12 to 15 months
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- May 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- GSK Investigational Site · Huntington Park, CA
- GSK Investigational Site · National City, CA
- GSK Investigational Site · West Covina, CA
Florida · 2
- GSK Investigational Site · Hialeah, FL
- GSK Investigational Site · Miami, FL
Illinois · 1
- GSK Investigational Site · Chicago, IL
Louisiana · 1
- GSK Investigational Site · Lafayette, LA
Minnesota · 1
- GSK Investigational Site · Mankato, MN
Nebraska · 1
- GSK Investigational Site · Lincoln, NE
Ohio · 1
- GSK Investigational Site · Cincinnati, OH
Texas · 4
- GSK Investigational Site · Dallas, TX
- GSK Investigational Site · Houston, TX
- GSK Investigational Site · Richmond, TX
- GSK Investigational Site · Richmond, TX
Utah · 1
- GSK Investigational Site · Syracuse, UT
Virginia · 1
- GSK Investigational Site · Richmond, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.